retatrutide safety profile More data on dropped today at the ADA conference!! Reta is an investigational -not FDA approved yet- once-weekly medication that simultaneously activates the GIP, GLP-1, and glucagon receptors In the Phase Retatrutide vs Tirzepatide: Which Weight-Loss

Description

There is no evidence that doses below these levels provide comparable benefits

Cardiometabolic conditions: at the highest dose, Tirzepatide has shown to improve cholesterol

Stimulating GLP-1R in BMSCs triggers the buildup of nuclear -catenin, which, in turn, activates osteogenic genes by binding with TCF7L12.371 In osteoblasts, the administration of GLP-1 and GIP incretins suppressed the excessive expression of the pro-degradative enzymes MMP-3 and MMP-13 induced by IL-1 stimulation.372 In vitro, GLP-1 disrupts the ability of osteoblasts to survive and differentiate by triggering the activation of c-Fos, which is a proto-oncogene.373 In fact, when BMSCs are exposed to exendin-4, the expression of genes related to bone development factors such as Runx and Osterix, as well as genes responsible for producing the bone matrix such as Balp and Bglap, is upregulated

Retatrutide is still investigational and not widely approved for clinical use, whereas Tirzepatide is already approved and more widely accessible

Some people titrate slowly, tolerate the low doses well, but never experience meaningful appetite suppression or weight loss until they reach standard therapeutic doses anyway